Histone acetyltransferases: challenges in targeting bi-substrate enzymes by Hannah Wapenaar & Frank J. Dekker
REVIEW Open Access
Histone acetyltransferases: challenges in
targeting bi-substrate enzymes
Hannah Wapenaar and Frank J. Dekker*
Abstract
Histone acetyltransferases (HATs) are epigenetic enzymes that install acetyl groups onto lysine residues of cellular
proteins such as histones, transcription factors, nuclear receptors, and enzymes. HATs have been shown to play a
role in diseases ranging from cancer and inflammatory diseases to neurological disorders, both through acetylations
of histone proteins and non-histone proteins. Several HAT inhibitors, like bi-substrate inhibitors, natural product
derivatives, small molecules, and protein–protein interaction inhibitors, have been developed. Despite their
potential, a large gap remains between the biological activity of inhibitors in in vitro studies and their potential use
as therapeutic agents. To bridge this gap, new potent HAT inhibitors with improved properties need to be
developed. However, several challenges have been encountered in the investigation of HATs and HAT inhibitors
that hinder the development of new HAT inhibitors. HATs have been shown to function in complexes consisting of
many proteins. These complexes play a role in the activity and target specificity of HATs, which limits the translation
of in vitro to in vivo experiments. The current HAT inhibitors suffer from undesired properties like anti-oxidant
activity, reactivity, instability, low potency, or lack of selectivity between HAT subtypes and other enzymes. A
characteristic feature of HATs is that they are bi-substrate enzymes that catalyze reactions between two substrates:
the cofactor acetyl coenzyme A (Ac-CoA) and a lysine-containing substrate. This has important—but frequently
overlooked—consequences for the determination of the inhibitory potency of small molecule HAT inhibitors and
the reproducibility of enzyme inhibition experiments. We envision that a careful characterization of molecular
aspects of HATs and HAT inhibitors, such as the HAT catalytic mechanism and the enzyme kinetics of small
molecule HAT inhibitors, will greatly improve the development of potent and selective HAT inhibitors and provide
validated starting points for further development towards therapeutic agents.
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Background
Many diseases are connected to aberrant patterns of
post-translational modifications of cellular proteins such
as acetylations of lysine residues [1, 2]. Several cellular
proteins including histones, transcription factors, nuclear
receptors, and enzymes are subject to lysine acetylations,
which play a key role in the regulation of their functions
[3]. Acetylations of lysine residues on histones are in-
volved in epigenetic regulation of gene transcription [4, 5].
Apart from histones, lysine acetylations of transcription
factors, such as Myc proto-oncogene protein (c-MYC),
p53, and nuclear factor kappa-light-chain-enhancer of
activated B cells (NF-κB), have been shown to influence
their promotor activities and specificities [6–8]. Lysine
acetylations of enzymes or nuclear receptors play import-
ant regulatory roles in their function [9, 10]. Furthermore,
lysine acetylations are involved in protein–protein interac-
tions via bromodomains [5] (Fig. 1). Reversible lysine
acetylations are mediated by histone acetyltransferases
(HATs), which install acetyl groups onto lysine residues,
and histone deacetylases (HDACs), which remove acetyl
groups from lysine residues (Fig. 1). HDACs have been
studied extensively, mainly for their role in cancer, and
two HDAC inhibitors are currently on the market [9, 10].
In contrast, no clinical applications of HATs have been de-
scribed until now. Nevertheless, HATs have been shown* Correspondence: f.j.dekker@rug.nl
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to play a role in diseases ranging from cancer and inflam-
matory diseases to neurological disorders [11–13].
In cancer, HATs have been shown to suppress as well
as to stimulate tumor growth and disease progression.
Acetylation of histones can lead to a less condensed
DNA and therefore more gene transcription [5]. If these
genes are (proto-)oncogenes, hyperacetylation might aid
in cancer progression, whereas less acetylation might
protect against disease. Indeed, histone hyperacetylation
was found in hepatocellular carcinoma, and acetylation
of a specific lysine on histone H3 (H3K18) was corre-
lated with prostate cancer recurrence [14, 15]. Lower
levels of H3K18 were shown to be advantageous for gli-
oma patients [16]. However, when investigating the
HATs themselves, they were found to have opposite ef-
fects, even within the same type of cancer. For example,
the KAT3B HAT gene was suggested to function as
tumor suppressor gene in colorectal cancer [17], but
high levels of KAT3B mRNA were correlated with pro-
gression of the disease [18]. Also in non-histone acetyl-
ation, HATs seem to exert counteracting effects. The
HATs KAT2A, 2B, and 5 acetylate the oncogene c-MYC
leading to increased stability of the c-MYC protein,
which may lead to cancer progression [6]. In contrast,
KAT2B also acetylates the tumor suppressor protein
p53 and activates its transcriptional activity, suggesting a
protective function for KAT2B [19]. The exact role of
HATs in cancer and the regulatory factors influencing
HATs are therefore still under investigation.
Histone acetylation and HAT activity are involved in
inflammatory diseases. The HATs KAT3A and KAT3B
were shown to activate the expression of pro-
inflammatory interleukins like IL-5, IL-8, and IL-4 [20–
22]. HATs also function as cofactors of NF-κB and activate
its transcriptional activity [23, 24]. NF-κB itself is acety-
lated by HATs on various positions, which influences pro-
motor activity and specificity [8]. In diabetic type-2
patients, inflammatory processes can increase insulin
resistance. NF-κB was shown to be recruited to gene
promotors under diabetic conditions, and an increase
of histone acetylation was observed in monocytes of dia-
betic patients [25]. An increase in the activity of HATs
was observed in blood monocytes of patients with asthma
[26]. In pulmonary fibrosis, it was shown that inhibiting
the KAT3A/β-catenin interaction attenuated and even re-
versed disease by influencing the Wnt signaling pathway
[27]. HATs have been shown to activate inflammatory
signaling and may therefore be promising targets for
treatment of inflammatory diseases. On the other
hand, however, a study on KAT2B showed that this
HAT was essential for inflammation-induced post-ischemic
arteriogenesis, suggesting that activation of KAT2B
can aid in recovery after ischemic events such as stroke or
myocardial infarction [28].
Genetic mutations or deletions of HAT genes have
severe consequences for neuronal development and
function [13]. A mutation in the KAT3A and KAT3B
genes causes the Rubinstein–Taybi syndrome. This
Fig. 1 Lysine acetylation is balanced by histone acetyltransferases (HATs) and histone deacetylases (HDACs). Acetylation of lysine residues on the
histone tails that protrude from the histone–DNA complex modifies the chromatin structure of the DNA, which allows transcription factors to
bind. The transcription factors themselves can be acetylated, which influences promotor activity and specificity. Lysine acetylation of enzymes or
nuclear receptors can influence their function. Bromodomain-containing proteins will bind to the acetylated lysine residues. Through lysine acetylations,
HATs are involved in many different diseases such as cancer, inflammatory diseases, and neurological disorders. NR nuclear receptor, BRD bromodomain,
NE nuclear enzyme, TF transcription factor
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disease is characterized by growth impairment, mental
retardation, and typical morphologies like broad
thumbs and halluces and distinct facial features [29].
Therefore, it is suggested that HATs play a role in
the maturation of neurons in embryonic development,
memory, learning, and even skeleton formation.
Most research on HATs and their role in diseases de-
pends on genetically modified mice and cellular studies.
These methods, however, have limitations. Knock-out
mice, for example, need to be viable to be studied, and
knock-out of many HAT genes is incompatible with life
[30–32]. Immortalized cell lines may behave very differ-
ently from the diseased or healthy situation, and little in-
formation on the molecular level can be derived from
these models. Therefore, drug discovery projects have
been initiated to identify small molecule inhibitors of
HAT activity that can be used for the development of
research tools to study their functions as well as the
exploration of their potential as targets for therapeutic
interventions [33, 34]. Despite their potential, the develop-
ment of small molecule inhibitors for HATs proved to be
challenging and a large gap remains between the bio-
logical activity of inhibitors in in vitro studies and their
use as therapeutic agents. To bridge this gap, new potent
HAT inhibitors with improved properties need to be de-
veloped. However, several challenges have been encoun-
tered in the investigation of HATs and HAT inhibitors
that hinder the development of new HAT inhibitors. In
this review, we will discuss these challenges and we
propose that careful investigation of the molecular aspects
of HAT function and inhibition will give a solid starting
point for the development of new potent and selective
HAT inhibitors with therapeutic potential.
The HAT enzymes—challenges in substrate specificity
The human HATs are classified as lysine (K) acetyltrans-
ferases (KATs). It should be noted that alternative no-
menclature, as indicated in Table 1, is frequently used as
well. Type B HATs (KAT1, HAT4) are cytoplasmic enzy-
mes—they modify free histones in the cytoplasm just
after their synthesis, upon which they are transported to
the nucleus and integrated in newly synthesized DNA
[35]. Type A HATs are (mainly) nuclear enzymes. They
are responsible for acetylations of histones and non-
histone proteins in the nucleus. Based on their se-
quence homology, most nuclear HATs can be assigned to
families. The GNAT (Gcn5-related N-acetyltransferases)
family consists of KAT2A and KAT2B. The MYST family
(after the members MOZ, YBF2/SAS3, SAS2, and TIP60)
is the largest family and consists of KAT5, 6A and 6B, 7,
and 8. The p300/CBP family consists of KAT3A and 3B.
Other HATs are the transcriptional co-activators, such as
KAT4 and KAT12, and steroid receptor co-activators,
such as KAT13A-D, that possess acetyltransferase activity
next to their other functions.
The HAT isoenzymes have various substrate specific-
ities for histone or non-histone proteins. For example,
the HATs KAT3A and 3B acetylate all four histone sub-
types (histone H2A, H2B, H3, and H4), but KAT6A
acetylates only histone H3 [36, 37] and KAT8 acetylates
specifically lysine 16 on histone H4 (H4K16) [38]. This
substrate specificity is modulated by the incorporation
of HATs in large multi-subunit protein complexes [39].
For example, KAT8 operates through two evolutionary
conserved protein complexes, the MSL-1 complex, and
the MSL1v1 complex. The acetylation activity of these
two protein complexes on histone H4 is identical, but
acetylation of the non-histone target p53 differs dramat-
ically [40]. It was also shown that recombinant KAT8,
free of interactions with proteins from either complex,
acetylated H2A and H3 as well as H4, in contrast to the
specificity of the KAT8 protein complexes for H4K16
[41]. Also in the case of KAT2A, incorporation into its
SAGA and Ada complexes influences the specificity and
the catalytic activity towards its histone targets as well as
its non-histone targets [42]. The influence of the HAT
protein complexes on acetyltransferase activity and sub-
strate specificity is one of the challenges that need to be
addressed in the development of small molecule HAT in-
hibitors, considering that the activities of recombinant
HAT enzymes may not reflect their in vivo activity. This
may limit the translation from in vitro assays to in vivo
disease models.
Table 1 Histone acetyltransferases: families, subtypes, and
alternative nomenclature frequently used












Transcription co-activators KAT4 TAF1, TBP
KAT12 TIFIIIC90
Steroid receptor co-activators KAT13A SRC1
KAT13B SCR3, AIB1, ACTR
KAT13C p600
KAT13D CLOCK
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HAT inhibitors—challenges in molecular properties
Parallel to functional studies on HATs, research has aimed
at developing small molecule inhibitors as research tools
or as potential therapeutic agents. Different approaches
such as construction of HAT substrate mimics, research
on natural products, and high throughput and virtual
screening have been used to identify HAT inhibitors.
One class of inhibitors is the bi-substrate inhibitors.
These inhibitors mimic the two HAT substrates: the cofac-
tor acetyl coenzyme A (Ac-CoA) and a peptide resembling
the lysine substrate, connected via a linker (Fig. 2). Bi-
substrate inhibitors have been made for KAT2B,
KAT3B, KAT5, and the yeast KAT5 homologue ESA1
[43, 44] and are very selective. They have been used as
dead-end inhibitors that mimic the natural substrate but
cannot be converted by the enzyme in kinetic studies [45].
However, due to their peptidic nature and their size, bi-
substrate inhibitors suffer from poor metabolic stability
and a lack of cell permeability, which limits their ap-
plications in cellular systems.
Several small molecule HAT inhibitors have been derived
from natural products. Among others, garcinol, curcumin,
and anacardic acid (Fig. 2) have shown to be HAT inhibi-
tors [46–48]. However, these natural products and close de-
rivatives are not selective between HATs and often have
many other targets [49, 50]. Many natural product HAT in-
hibitors contain phenolic structures, which are prone to
oxidation. As a result, it is often hard to determine whether
the observed effects in advanced disease models are due to
inhibition of HAT activity or due to anti-oxidant properties.
Fig. 2 The current HAT inhibitors and activators. Bi-substrate inhibitors mimic the two HAT substrates: Ac-CoA, connected via a linker to a peptide
resembling the lysine substrate. Garcinol, curcumin, and anacardic acid are natural product HAT inhibitors. Small molecule inhibitors C646 and
thiazinesulfonamide were discovered from a virtual screening. A high throughput screening yielded isothiazolone derivatives. A pentamidine
derivative, TH1834, and a benzylidene barbituric acid derivative were developed using a structure-based design. ICG-001 is a protein–protein
interaction inhibitor and inhibits the interaction between KAT3A and β-catenin. HAT bromodomain inhibitors have been developed for KAT3A and
KAT2B, including the natural product ischemin, a set of cyclic peptides and small molecule N1-aryl-propane-1,3-diamine derivatives. CTPB, TTK21, and
SPV106 are salicylic acid-derived HAT activators. CTBP activates KAT3B, TTK21 activates both KAT3B and KAT3A, and SPV106 interestingly is a KAT2B
activator and KAT3A/3B inhibitor
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For other natural products such as anacardic acid, their
lipophilic and amphiphilic character is a limiting factor for
further exploration and optimization. Nevertheless, promis-
ing cellular effects have been observed for this type of HAT
inhibitors. The natural product HAT inhibitors garcinol
and anacardic acid have been shown to sensitize cancer
cells to irradiation [51, 52]. Garcinol suppressed prolifera-
tion of breast cancer cells and inhibited colon carcinogen-
esis in mice [53, 54]. Curcumin is indeed a HAT inhibitor,
but its biological effect cannot be solely appointed to HAT
inhibition. Curcumin is an anti-oxidant and additionally
contains a Michael acceptor that can react with nucleo-
philes present in cells, like thiols or anions of alcohols [55].
It can, therefore, influence many processes in the cell, unre-
lated to HAT inhibitory activity. Nevertheless, curcumin is
currently in clinical trials for many applications as a thera-
peutic agent, combination therapy, or dietary supplement
(Table 2), although it must be noted that measurements on
HATs or their activities are not included in the outcome
parameters of these trials. Recently, promising results have
been obtained with a structure-based design to improve
natural product HAT inhibitors. Modification of the struc-
ture of pentamidine lead to the inhibitor TH1834, and a
benzylidene barbituric acid derivative with improved
selectivity and cell permeability was developed from garci-
nol [56, 57]. Thus, although natural products may suffer
from undesired properties, they form excellent starting
points for further development of HAT inhibitors (Fig. 2).
Other methods like virtual or high throughput screening
have yielded small molecule HAT inhibitors with diverse
structures (Fig. 2). In high throughput screening, large
numbers compounds are tested in an enzyme inhibition
assays. Originating as hits from a high throughput screen-
ings, isothiazolones have been developed as inhibitors for
various subtypes of HATs and proved to inhibit prolifera-
tion in cancer cell lines [58–60]. However, most of these
isothiazolones are highly reactive towards thiolates,
which limits their applicability in biological systems
[61]. In virtual screening methods, the crystal structure
or homology model of the target protein is used to
computationally screen virtual databases of compounds
for potential binding. The KAT3B HAT inhibitor 4-
acetyl-2-methyl-N-morpholino-3,4-dihydro-2H-ben-
zo[b][1, 4]thiazine-7-sulfonamide (Fig. 2, thiazinesulfona-
mide) was discovered using virtual screening on
KAT3B [62]. The inhibitor C646 has been discovered
using the same method and is currently the most potent
and selective small molecule KAT3B HAT inhibitor [63].
Table 2 HAT inhibitors and activators, their target histone acetyltransferases, and proposed target pathologies
HATs Proposed target pathologies References
HAT inhibitors
Bi-substrate inhibitors Various – [43–45]
Garcinol KAT3B Breast cancer, colon carcinoma [48, 52–54]
Curcumin KAT3B Cancer, inflammation, neurological disorders, cardiovascular
disease, metabolic diseasesa
[47], clinicaltrials.gov
Anacardic acid Non-selective Sensitizing cancer cells to irradiation [46, 51]
TH1834 KAT5 Breast cancer [56]
Benzylidene barbituric acid KAT3B Cell cycle arrest, increase in hypodiploid nuclei [57]
Isothiazolones various Inhibition of cancer cell proliferation [58–61]
Thiazinesulfonamide KAT3B – [62]
C646 KAT3B Prostate cancer, melanoma, leukemia, peritoneal fibrosis [63–68]
ICG-001 KAT3A/β-
catenin
Investigation of the KAT3A/β-catenin interaction in survivin
gene transcription, colon carcinoma
[70, 71]
Ischemin (bromodomain inhibitor) KAT2A and 2B,
KAT3A and 3B
Myocardial ischemia [73]





CTPB KAT3B – [46]
TTK21 KAT3A and 3B Neurogenesis and long-term memory, brain disease [76]
Pentadecylidenemalonate KAT2B Conditioned fear, wound repair, cardiovascular disease,
diabetes
[77]
aCurcumin is currently in clinical trials for many applications as a therapeutic agent, combination therapy, or dietary supplement, although measurements on HATs
or their activities were not included in the outcome parameters of these trials
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Since its discovery in 2010, this inhibitor has been shown
to be active in different cellular models of cancer. Among
others, it inhibited proliferation of prostate cancer and
melanoma cells, induced cell cycle arrest in leukemia cells,
and sensitized lung cancer cells to irradiation [64–67].
Also for other implications, as peritoneal fibrosis, this in-
hibitor recently showed promising results [68]. This shows
that screening methods are valuable for the discovery of
HAT inhibitors with novel structures and are expected to
yield more inhibitors in the near future.
Another way of inhibiting HAT function, in contrast
to inhibiting the acetyltransferase activity, is to target
protein–protein interactions between HATs and their
interaction partners. HATs interact with many proteins
and influence their function, in some cases independent
of their acetyltransferase activity. KAT3A, for example,
was shown to activate β-catenin, a transcription factor
involved in inflammatory signal transduction, independ-
ent of its acetyltransferase activity [69]. The inhibitor
ICG-001 (Fig. 2) inhibits the interaction between
KAT3A and β-catenin, and the inhibition was shown to
be selective over the interaction between KAT3B
and β-catenin [70]. Studies with this inhibitor re-
vealed a different role for the KAT3A/β-catenin than
for the KAT3B/β-catenin interaction in survivin gene
transcription [71]. Therefore, protein–protein inter-
action inhibitors can be used to selectively explore
the functions of HATs that are not mediated by the
enzymatic acetyltransferase activity. These studies
additionally revealed anti-cancer activity in colon
carcinoma models for this inhibitor, showing that
inhibition of the KAT3A/β-catenin interaction has
therapeutic potential.
Several HATs (KAT2A and 2B, KAT3A and 3B) contain
a bromodomain, which can bind specifically to acetylated
lysine residues. Bromodomain inhibitors target this inter-
action by preventing the binding of the acetylated lysine
to the bromodomain [72]. HAT bromodomain inhibitors
have been developed for KAT3A and KAT2B, including
the natural product ischemin, a set of cyclic peptides and
small molecule N1-aryl-propane-1,3-diamine derivatives
[73–75] (Fig. 2). In contrast to the aforementioned inhibi-
tors, these inhibitors do not seem to have potential as
anti-cancer agents. The cyclic peptides were developed as
inhibitors of the tumor suppressor protein p53, having
opposite function as anti-cancer agents [74]. Ischemin
inhibited apoptosis in cardiomyocytes, showing potential
as therapeutic in myocardial ischemia and [73] the small
molecule N1-aryl-propane-1,3-diamine derivatives showed
an inhibitory effect on HIV-1 replication, opening possi-
bilities as anti-viral agents [75]. This shows that HAT in-
hibitors have more potential than anti-cancer agents alone
and can possibly be used as therapeutics for many more
indications.
A small number of positive modulators or activators
of HATs have been described (Fig. 2). The KAT3B se-
lective activator N-(4-chloro-3-trifluoromethyl-phenyl)-
2-ethoxy-6-pentadecyl-benzamide (CTPB) was derived
from the natural product HAT inhibitor anacardic acid
and was shown to activate gene transcription [46]. The
activator TTK21 was also based on a salicylic acid struc-
ture but was shown to activate both KAT3A and 3B. This
activator improved memory duration in mice and was
suggested to have opportunities for application in brain
disease [76]. Another anacardic acid-based KAT2B activa-
tor is the pentadecylidenemalonate SPV106. Interestingly,
this compound activates KAT2B but was shown to inhibit
KAT3A and 3B [77]. This HAT modulator has been
shown to have a positive effect in models of cardiovascular
disease, diabetes, wound repair, and the extinction of con-
ditioned fear [78–82]. These examples show that both for
inhibitors and activators or mixed activator/inhibitors of
HATs, there may be future clinical applications (Table 2).
Catalytic mechanism—challenges in substrate conversion
HATs catalyze the acetylation of lysine residues using the
cofactor Ac-CoA as an acetyl donor. HATs are therefore
bi-substrate enzymes, i.e., they bind and convert two sub-
strates in the process of catalysis. Although all HATs
acetylate lysine residues and use Ac-CoA as a cofactor, the
mechanism of catalysis differs. In theory, there are three
standard catalytic mechanisms for bi-substrate enzymes:
(i) a random-order ternary complex mechanism, (ii) a
compulsory-order ternary complex mechanism, or (iii) a
ping-pong mechanism. In a random-order ternary com-
plex mechanism, either substrate can bind first to the en-
zyme, in a random order. The acetyl group is directly
transferred from Ac-CoA to the lysine residue upon for-
mation of the ternary complex by binding of the second
substrate. In a compulsory-order ternary complex mech-
anism, a ternary complex is formed, but one of the sub-
strates has to bind first before the other substrates can
bind. In both mechanisms, catalysis depends on the pres-
ence of a general base, such as glutamic acid, which facili-
tates the nucleophilic attack on the Ac-CoA thioester by
deprotonating the lysine residue. In a ping-pong mechan-
ism, Ac-CoA binds first and the acetyl group is transferred
to an amino acid in the catalytic site of the enzyme. CoA
leaves the enzyme and subsequently the substrate binds,
to which the acetyl group is transferred. This mechanism
requires, next to a general base, an amino acid in the cata-
lytic site of the enzyme suitable for accepting the acetyl
group, which is commonly a cysteine [83]. Knowledge
on the catalytic mechanism plays an important role in the
characterization and development of small molecule en-
zyme inhibitors. This has for example been shown for the
well-known NAD+ dependent liver alcohol dehydrogen-
ase, which operates via a compulsory-order ternary
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complex mechanism, where NAD+ must bind first [84,
85]. The development of inhibitors was greatly aided by
knowledge on the catalytic mechanism of the alcohol
dehyrogenase. Also, in the case of HATs, definition of the
catalytic mechanisms is highly important.
There is evidence that the GNAT family HATs catalyze
lysine acetylation by a ternary complex mechanism.
These enzymes contain a conserved glutamic acid
(KAT2A: Glu-173; KAT2B: Glu-570) in the active site,
which can serve as general base that deprotonates the
positively charged lysine to allow nucleophilic attack on
the Ac-CoA thioester [86]. This mechanism is supported
by a kinetic study on KAT2B using two-substrate kinetic
analysis and a dead-end inhibitor that mimics CoA, but
cannot be converted by the enzyme. The study showed
that this enzyme follows a compulsory-order ternary
complex mechanism in which Ac-CoA binds first to the
enzyme followed by the histone substrate [87]. There-
fore, the current consensus is that the GNAT family
HATs catalyze lysine acetylation through a compulsory-
order ternary complex mechanism.
For MYST family proteins, studies have described dif-
ferent catalytic mechanisms. For the MYST family HAT
KAT8, a kinetic study on the recombinant catalytic do-
main, showed a pattern consistent with a ping-pong
mechanism in which the acetyl moiety is transferred
onto a residue in the active site of the enzyme. The sub-
sequent binding of Ac-CoA and the histone peptide was
confirmed by calorimetric binding measurements [88].
KAT8 contains the conserved glutamic acid, Glu-177,
which can act as a general base as well as a cysteine in
the catalytic site, Cys143, which is capable of accepting
the acetyl moiety in case of a ping-pong mechanism
[PDB: 3TOA [89]]. In a study with the catalytic domain
of ESA1, a MYST family HAT from yeast that shows
close homology to human KAT5 and KAT8, it was
shown that cysteine 304 (Cys-304) and glutamic acid
338 (Glu-338) are both essential for enzyme activity.
Glu-338 was shown to function as a general base, as in
GNAT family HATs [90]. A crystal structure of trun-
cated ESA1 co-crystallized with Ac-CoA showed that
the acetyl moiety of Ac-CoA had transferred from the
cofactor to Cys-304, supporting a ping-pong mechanism
[91]. However, this was countered by a study showing
that mutation of Cys-304, in contrast to the aforemen-
tioned study, did not impair the activity of the enzyme
and kinetic studies showed a pattern indicating catalysis
via a ternary complex mechanism [92]. In this study, not
the catalytic HAT domain, but full-length ESA1 was
used and it was combined with two other proteins form-
ing the piccolo NuA4 complex, which is naturally occur-
ring in yeast. This shows that the catalytic mechanism of
ESA1 was influenced by the interaction with other pro-
teins. Therefore, just as the substrate specificity and
acetyltransferase activity of HATs is influenced by the in-
corporation into HAT protein complexes, these com-
plexes may influence the catalytic mechanism as well.
As for MYST family enzymes, the catalytic mechanism
for the p300/CBP family depends on the experimental
methods applied in the respective study. Based on kinetic
measurements with the recombinant full-length enzyme,
it was proposed that KAT3B uses a ping-pong mechanism
[93]. Studies using an Ac-CoA-based probe that targets
cysteine residues showed that the probe bound a cysteine
residue in the catalytic domain of KAT3B, which was im-
portant for Ac-CoA binding. However, the catalytic activ-
ity of KAT3B was not abolished by mutation of this
cysteine residue, which would be expected in a ping-pong
mechanism [94]. The possibility of a ternary complex
mechanism was investigated by comparing the affinity
pattern of different bi-substrate inhibitors [95]. In a tern-
ary complex mechanism, inhibitors with a longer peptide
part should have better affinity, but in case of KAT3B, it
was shown that the shortest inhibitor was most potent.
Therefore, it was proposed that KAT3B uses a Theorell–
Chance (“hit-and-run”) catalytic mechanism. In the Theo-
rell–Chance mechanism, there is no stable ternary com-
plex. Ac-CoA binds first and subsequently, the peptide
substrate binds weakly to the enzyme, allowing the lysine
to react with the acetyl group. However, kinetically only
the interaction with Ac-CoA is important [95]. In studies
on the catalytic mechanism of KAT3B, kinetic measure-
ments, affinity labeling-based probes, substrate mimic in-
hibitors, crystallization, and mutagenesis studies, resulted
in proposals for different mechanisms. This shows that
using a single method may not be sufficient to conclude
on the catalytic mechanism of HATs.
So far, different studies indicate different catalytic
mechanisms for specific HATs. The use of different con-
structs of the HAT enzymes and the use of different
methods leads to different proposed catalytic mechanisms.
Table 3 summarizes the proposed catalytic mechanisms
for different HAT families, the enzyme constructs that are
used, and methods that are applied. We note that, inde-
pendent from the mechanism found, all HATs seem to
conserve both a glutamic acid, which can function as a
general base to deprotonate the lysine residue, and a
cysteine residue, which can serve as acetyl acceptor in
the formation of acetylated enzyme intermediate in a
ping-pong mechanism. Nevertheless, despite the presence
of this cysteine residue, it is not in all cases critical for
catalysis. Apparently, the methods used in these studies
cannot distinguish between the types of mechanisms for
these HATs, which may indicate that both mechanisms
could occur, depending on the methods used and the con-
ditions applied. If the energetic profile for the different
catalytic mechanisms is very similar, small changes in
assay conditions could lead to the observation of different
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catalytic mechanisms. This may indicate that HATs are
flexible enzymes which can act via different catalytic
mechanisms under different conditions.
HAT inhibitors—challenges in inhibitor kinetics
The fact that HATs are bi-substrate enzymes does not
only affect the analysis of their catalytic mechanisms but
also has consequences for the development of small
molecule inhibitors for these enzymes. To characterize
the potency of such inhibitors, they are often tested in
steady-state enzyme inhibition assays. From these assays,
the concentrations that give 50 % inhibition of the en-
zyme activity (IC50) are derived. However, these values
depend on the assay conditions, and therefore, reporting
the inhibitory potency (Ki) is preferred. The Ki value
allows for better reproducibility between enzyme in-
hibition assays and is therefore important for further
development of potent and selective inhibitors. In case of
a single-substrate enzyme and a competitive inhibitor, the
IC50 can be corrected for the assay conditions using the
Cheng–Prusoff equation using the substrate concentration
and the Michaelis constant (Km) of the substrate [96].
However, in case of bi-substrate enzymes like HATs,
additional factors influence the IC50, namely the catalytic
mechanism, the concentration of both substrates, and
their respective Michaelis constants [83, 96]. The KAT3B
inhibitor C646 was shown to be competitive with Ac-CoA
and non-competitive with the histone substrate [63].
Further studies showed that the level of inhibition by
C646 was not time-dependent and that pre-incubation
did not influence the level of inhibition, showing that it is
a reversible inhibitor. A Ki value was derived from the
Dixon plots, which seems to be justified considering the
described mechanism. There are, however, few reports on
the calculation of Ki values in case of a Theorell–Chance
mechanism, except in case of bi-substrate analogue dead-
end inhibitors [97]. The Ki value of C646 was shown to be
3.2-fold lower than the IC50, showing the significance of
the calculation of this value. Although not aimed at calcu-
lating the inhibitory potency, an interesting mechanistic
investigation of garcinol and two derivatives used calori-
metric binding studies and kinetic evaluations to propose
a mechanism for the binding of these inhibitors [98]. An
enzyme kinetic study on inhibition of the MYST family
HAT KAT8 by the natural product HAT inhibitor anacar-
dic acid revealed a more complicated binding model [88].
This enzyme proved to catalyze histone acetylation
via a ping-pong mechanism, and according to the enzyme
kinetics, the inhibitor proved to bind to the acetylated en-
zyme intermediate. This information enabled the calcula-
tion of the Ki value for KAT8 inhibition by anacardic acid
and several derivatives, using an equation reported by
Cheng and Prusoff [96]. Also in this case, the Ki values of
anacardic acid were more than threefold lower compared
to the IC50 values under the applied assay conditions.
These examples underline the importance of the deter-
mination of the kinetic mechanisms and the calculation of
Ki values.
Considering the dependence of the IC50 values on the
Km values and concentrations of both substrates, it is
clear that IC50 values are prone to variations between
different studies and assay set-ups. Nevertheless, very
few studies have currently been reported in which the
mechanism of inhibition and Ki values of existing HAT
inhibitors have been calculated. This does, however, pose
problems for further development of HAT inhibitors. It
is, for example, not possible to compare the potencies of
the new inhibitors with the potencies of existing inhibitors,
unless exactly the same assays with the same conditions
are used. In addition, it is often overlooked that it is not
possible to conclude on selectivity of an inhibitor based on
IC50 values, especially in the case of bi-substrate enzymes
in which IC50 values strongly depend on both substrates
and the catalytic mechanism. Therefore, it is important to
investigate the enzyme kinetics of HAT inhibitors carefully,
using multiple methods (Fig. 3). This will aid in deriving a
Table 3 Reported catalytic mechanisms for the different HAT families, the enzyme constructs used, and experimental methods
applied
Family Mechanism Enzyme (amino acids) Methods Reference
GNAT Compulsory-order ternary
complex mechanism
KAT2A HAT domain (99–262) Mutagenesis studies, biochemical studies [86]
KAT2B catalytic domain (493–676)
and full-length
Kinetic analysis, dead-end substrate mimic
inhibitor
[45]
MYST Ping-pong mechanism Yeast ESA1 HAT domain (160–435) Crystal structure, mutagenesis [91]
KAT8 C-terminal (125–458) Kinetic analysis, calorimetric binding studies [88]
Ternary complex mechanism Yeast ESA1 full-length and picNuA4 complex Kinetic analysis, mutagenesis studies [92]
p300/CBP Ping-pong mechanism KAT3B full-length Kinetic analysis [93]
Theorell-Chance mechanism KAT3B catalytic domain (1284–1673) Chemical probe [94]
KAT3B semi-synthetic heterodimeric HAT
domain (1287–1652)
Crystal structure, bi-substrate inhibitor,
mutagenesis, kinetic analysis
[95]
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Ki value for the inhibitors and increase the understanding
of HAT enzymes, which will facilitate the further develop-
ment of novel potent and specific HAT inhibitors.
Conclusions
HATs are upcoming targets in drug discovery with poten-
tial applications in many disease models. Nevertheless, as
our knowledge is progressing, the challenges in targeting
these enzymes become more and more clear. One of the
challenges is that HATs have various cellular substrates
ranging from histones and transcription factors to en-
zymes and nuclear receptors. In addition, they operate as
part of multi-protein complexes, which determine their
functions, their enzymatic activities and their substrate
specificities. This complicates the translation of studies on
recombinant enzymes to cellular studies and more ad-
vanced (in vivo) disease models. The challenges in the de-
velopment of small molecule inhibitors of HAT activity
have been addressed over recent years, but most of the
resulting inhibitors still suffer from undesired properties
such as anti-oxidant activity, instability in a cellular envir-
onment, low potency, or lack of selectivity between HAT
subtypes and other enzymes.
Another important challenge is the understanding of
the catalytic mechanisms of HAT activity in relation to
enzyme kinetics of small molecule HAT inhibitors. As
bi-substrate enzymes, HATs catalyze the reaction between
two substrates, the cofactor Ac-CoA and the lysine resi-
due on the target protein. The catalytic mechanism, by
which these substrates are converted by HATs, is influ-
enced by the enzyme length and the experimental
methods applied to measure the enzyme activity. Further-
more, the presence of other proteins that can modulate
HAT activity by the formation of protein–protein com-
plexes can also affect the catalytic mechanism. Despite the
difficulties of investigating the catalytic mechanism, know-
ledge on the catalytic mechanism is very important for
further understanding of how HATs work and for the de-
velopment of inhibitors that are potent and selective.
Combined with the catalytic mechanism of the HAT en-
zyme, inhibitor kinetics can enable the calculation of assay
independent inhibitory constants (Ki). The ability to calcu-
late the inhibitory potency of inhibitors will enable com-
parison with existing HAT inhibitors and determination
of the selectivity. This will greatly enhance the discovery
of HAT inhibitors and improve their chances to be taken
into further development as research tools or therapeutic
agents.
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